CRANFORD, N.J., June 22, 2020 /PRNewswire/ -- Citius
Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a
specialty pharmaceutical company focused on developing and
commercializing critical care drug products, announced today that
Chief Executive Officer Myron
Holubiak will deliver a virtual presentation at the Life
Sciences Investor Forum on Thursday, June
25, 2020 at 11:00 AM
ET.
Event: Life Sciences
Investor Forum
Presentation Date:
Thursday, June 25, 2020
Presentation Time:
11:00 AM ET
Mr. Myron Holubiak will present
an update on the Company, including its Phase 3 pivotal trial with
Mino-Lok® that is currently more than half enrolled and its option
to license a novel stem cell therapy for acute respiratory distress
syndrome (ARDS) in COVID-19 patients. This presentation will be a
live, interactive online event where investors can ask the Company
questions in real-time. An archived webcast will also be made
available after the event.
While attendance at this virtual event is free, it is
recommended that investors pre-register at
www.lifesciencesinvestorforum.com.
About Citius Pharmaceuticals, Inc.
Citius is a specialty pharmaceutical company dedicated to the
development and commercialization of critical care products, with a
focus on anti-infectives, cancer care, and unique prescription
products that use innovative, patented, or proprietary formulations
of previously-approved active pharmaceutical ingredients. We seek
to achieve leading market positions by providing therapeutic
products that address unmet medical needs. By using
previously approved drugs with substantial safety and efficacy
data, we seek to reduce the risks associated with pharmaceutical
product development and regulatory requirements. Citius develops
products that have intellectual property protection and competitive
advantages to existing therapeutic approaches. For more
information, please visit www.citiuspharma.com.
About Life Sciences Investor Forum
Life Sciences
Investor Forum is a leading proprietary investor conference series
that provides an interactive forum for life sciences companies to
meet with and present directly to investors. It is a realtime
solution for investor engagement that is powered by Intrado Digital
Media and specifically designed for more efficient investor access.
Replicating the look and feel of on-site investor conferences, Life
Sciences Investor Forum combines leading-edge conferencing and
investor communications capabilities with a comprehensive global
investor audience network.
Safe Harbor
This press release may contain
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Such statements are made based on our
expectations and beliefs concerning future events impacting Citius.
You can identify these statements by the fact that they use words
such as "will," "anticipate," "estimate," "expect," "should," and
"may" and other words and terms of similar meaning or use of future
dates. Forward-looking statements are based on management's current
expectations and are subject to risks and uncertainties that could
negatively affect our business, operating results, financial
condition and stock price. Factors that could cause actual
results to differ materially from those currently anticipated are:
risks associated with conducting our Phase 3 trial for Mino-Lok,
including completing patient enrollment, opening study sites and
achieving the required number of catheter failure events; the
estimated markets for our product candidates and the acceptance
thereof by any market; our need for substantial additional funds;
risks associated with developing Mino-Wrap, including that
preclinical results may not be predictive of clinical results and
our ability to file an IND; risks related to our growth strategy;
our ability to identify, acquire, close and integrate product
candidates and companies successfully and on a timely basis; risks
relating to the results of research and development activities;
uncertainties relating to preclinical and clinical testing; the
early stage of products under development; our ability to obtain,
perform under and maintain financing and strategic agreements and
relationships; our ability to attract, integrate, and retain key
personnel; government regulation; patent and intellectual property
matters; competition; as well as other risks described in our SEC
filings. We expressly disclaim any obligation or undertaking to
release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in our
expectations or any changes in events, conditions or circumstances
on which any such statement is based, except as required by
law.
Contact:
Andrew
Scott
Vice President, Corporate
Development
(O) 908-967-6677 x105
ascott@citiuspharma.com
View original
content:http://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-deliver-virtual-presentation-at-the-life-sciences-investor-forum-301081174.html
SOURCE Citius Pharmaceuticals, Inc.